Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1387-1395

  Fiorentini, Giammaria ^a   Aliberti, Camillo ^b   Tilli, Massimo ^c   Mulazzani, Luca ^a   Graziano, Francesco ^a   Giordani, Paolo ^a   Mambrini, Andrea ^d   Montagnani, Francesco ^e   Alessandroni, Paolo ^a   Catalano, Vincenzo ^a   Coschiera, Paolo ^a  

^a Azienda Ospedaliera Ospedali Riuniti Marche Nord   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Delta Hospital   (Italy)

^d General Hospital   (Italy)

^e General Hospital   (Italy)

Author keywords

Angiography; Chemoembolization; Colorectal cancer; DEBIRI; Drug eluting beads; FOLFIRI; Irinotecan; KRAS; Liver metastases; p53

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG ELUTING BEAD; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SUSTAINED RELEASE PREPARATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84859971752     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombert M and Boyle P: estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007. (Pubitemid 46359643)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin 59(4): 225-249, 2009.
3. Van Cutsem E, Nordlinger B, Adam R, Kohnr CH, Pozzo G, Ychou M and Rougier P on behalf of the European Colorectal Metastases Treatment Group: Towards a pan-Europeran consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42: 2212-2221, 2006.
4. Kemeny NE, Kemeny MM and Lawrence TS: Liver metastases. In:Abeloff MD, Armitage JO, Niederhuber JE and Lichter AS: Clinical Oncology, Third ed. Philadelphia: Elsevier Clinical Oncology pp. 1141-1178, 2004.
5. Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-318; discussion 318-321, 1999.
6. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, maroun JA, Ackland SP, Locker PK, Pirrotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 545: 905-914, 2000.
7. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MO, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ and Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J Clin Oncol 23: 9243-9249, 2005.
8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24: 3347-3353, 2006. (Pubitemid 46638888)
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
11. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L,Jaffe C, Rubinstein L, Zwiebel J and Kaplan RS: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24: 3354-3360, 2006. (Pubitemid 46638889)
12. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH and Kylstra JW: Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 12: 318-326, 2006. (Pubitemid 44285559)
13. Berber E, Pelley R and Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 23: 1358-1364, 2005.
14. Mocellin S, Pasquali S and Nitti D: Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.Cochrane Database sys rec 8;(3): CD007823, 2009.
15. Harmantas A, Rotstein LE and Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 78: 1639-1645, 1996.
16. Kerr DJ, Mc Ardle CS, Ledermann J, Taylor I, Sherlock DJ, Schlag PM, Buckels J, Mayer D, Cain D and Stephens RJ: Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361: 368-373, 2003. (Pubitemid 36164968)
17. Fiorentini G, Rossi S, Dentico P, Bernardeschi P, Calcinai A, Bonechi F, Cantore M, Guadagni S and De Simone M: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 89(4): 382-384, 2003. (Pubitemid 37279918)
18. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, hermdon JE 2nd, Zhang C and Mayer RJ: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24: 1395-1403, 2006. (Pubitemid 46622004)
19. Fiorentini G: A new tool to enhance the efficacy of chemoembolization to treat primary and metastatatic hepatic tumors. Expert Opin Drug Deliv 8(4): 409-413, 2011.
20. Vogl TJ, Zangos S, Eichler K, Yakoub D and Nabil M: Colorectal liver metastases:regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 17(4): 1025-1034, 2007. (Pubitemid 46766884)
21. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J: Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002. (Pubitemid 34607087)
22. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. Anticancer Res 26: 3793-3796, 2006.
23. Morise Z, Sugioka A, Kato R, Fujita J, Hoshimoto S and Kato T: Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. J Gastrointest Surg 10(2): 249-258, 2006. (Pubitemid 43187188)
24. Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G and Giovanis P: Intra-arterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 21: 1085-1091, 2007.
25. Fiorentini G, Aliberti C, Montagnani F, Tilli M, Mambrini A and Benea G: trans-arterial chemoembolization of metastatic coloretal carcinoma (MCRC) to the liver adopting polyvinyl alcohol microspheres (PAM) loaded with irinotecan compared with FOLFIRI (CT): evaluation at two years of a Phase III clinical trial. Ann Oncol 21(suppl 89): viii 198-vii 224, 2010.
26. Salman HS, Cynamon J, Jagust M, Bakal C, Rozenblint A, Kaleva R, Negassa A and Wadler S: Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2: 173-179, 2002. (Pubitemid 36013668)
27. Fiorentini G, Aliberti C, Benea G, Montagnani F, Mambrini A, Ballardini PL and Cantore M: TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post- procedure supportive therapy on the control of side-effects. Hepatogastroenterology 55(88): 2077-2082, 2008.
28. Taylor RR, Tang Y, Gonzalez MV, Stratford PW and Lewis AL: Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30: 7-14, 2007. (Pubitemid 44908921)
29. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, Leppard SW, Wolfenden LC, Palmer RR, Stratford PW: DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17: 335-342, 2006. (Pubitemid 44341453)
30. Lewis AL and Holden RR: DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. Expert Opin Drug Deliv 8(2): 153-169, 2011.
31. Nekolaichuk C, Watanabe S and Beaumont C: The Edmonton Symptom Assessment System: a 15-year retrospective review of validation studies (1991-2006). Palliat Med 22(2): 111-122, 2008. (Pubitemid 351597272)
32. Brown DB, Gould JE, gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC:Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20(7 Suppl): S425-434, 2009.
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
34. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759, 2007. (Pubitemid 46797957)
35. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM and Bruix J: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma:are response evaluation criteria in solid tumors reliable? Cancer 115: 616-623, 2009.
36. Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C, Ciardiello F, Nappi O, Iaffaioli RV, Botti G and Normanno N: Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11(8): 1169-1179, 2010.
37. Gallagher DJ, Capanu M, Raggio G and Kemeny N: hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin a retrospective analysis. Ann Oncol 18(12): 1995-1999, 2007. (Pubitemid 350286238)
38. Kemeny N, Jarnagin W, Paty P, Gönen M, Schwartz L, Morse M, Leonard G, D'Angelica M, DeMatteo R, Blumgart L and Fong Y: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23(22): 4888-4896, 2005. (Pubitemid 46223994)